MedTrace Logo

Research on Novel Biomarkers for Early Diagnosis of Parkinson's Disease:An Observational, Multicenter, Non-Randomized Controlled Study

NCT06232772 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2025-04-16

No results posted yet for this study

Summary

This observational, multicenter, non-randomized controlled study is to evaluate the detection ability of α-Synuclein Ultrafine Fluorescence Detection Method for body fluids (Such as saliva, urine, cerebrospinal fluid, and blood, etc.) and skin in Parkinson's patients.

Conditions

Interventions

DIAGNOSTIC_TEST

α- Synuclein Ultrafine Fluorescence Detection Method

This technology belongs to the detection of a-syn aggregates in extracranial tissues, which can replace brain biopsy operations that are difficult to carry out clinically, thus breaking through the limitations of clinical experience in diagnosing a-synuclein lineage diseases and greatly improving the diagnostic and differential diagnostic level of this group of diseases.

Sponsors & Collaborators

  • The First Affiliated Hospital of Guangzhou Medical University

    collaborator OTHER

  • First Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER

  • The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine

    collaborator UNKNOWN

  • Guilin Medical College

    collaborator OTHER

  • Guangxi International Zhuang Medical Hospital

    collaborator UNKNOWN

  • Yousheng Xiao

    lead OTHER

Principal Investigators

  • Yousheng Xiao, Professor · Guangxi Medical University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-03-31
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06232772 on ClinicalTrials.gov